About Seronegative Myasthenia

Overview

Seronegative myasthenia refers to a subtype of myasthenia gravis (MG) in which patients do not have detectable antibodies against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK).

People with seronegative MG may have less severe symptoms compared to people with seropositive MG. Some treatments, such as intravenous immunoglobulin (IVIG), may not work as well for people with seronegative MG.

Seronegative and seropositive MG are also similar:

• Immunotherapy: Seronegative myasthenia can still respond to immunotherapy, such as corticosteroids and plasma exchange.
• Myasthenic Crisis: Up to one fifth of all MG patients, including those with seronegative myasthenia, may experience a myasthenic crisis characterized by respiratory failure and difficulty managing secretions. Prompt medical attention is crucial during a crisis. Hospitalization may be needed to support breathing during a crisis.
• Ocular Myasthenia: Most MG patients, including those with seronegative myasthenia, eventually develop ocular symptoms due to the effect of myasthenia on the muscles that control the eyes and eyelids. Symptoms of ocular myasthenia include drooping eyelids and double vision. About 17% may have exclusive ocular myasthenia initially, which can progress to generalized symptoms within two years.

It is important to note that the prognosis and response to treatment can vary among individuals with seronegative myasthenia. Consulting with a healthcare professional is crucial for personalized management.